Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec;142(22):2095-2106.
doi: 10.1161/CIRCULATIONAHA.120.048792. Epub 2020 Oct 9.

Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study

Affiliations
Clinical Trial

Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study

Benedikt Schrage et al. Circulation. 2020 Dec.

Abstract

Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial recovery. The Impella unloads the left ventricle. This study aimed to evaluate whether left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO was associated with lower mortality.

Methods: Data from 686 consecutive patients with cardiogenic shock treated with VA-ECMO with or without left ventricular unloading using an Impella at 16 tertiary care centers in 4 countries were collected. The association between left ventricular unloading and 30-day mortality was assessed by Cox regression models in a 1:1 propensity score-matched cohort.

Results: Left ventricular unloading was used in 337 of the 686 patients (49%). After matching, 255 patients with left ventricular unloading were compared with 255 patients without left ventricular unloading. In the matched cohort, left ventricular unloading was associated with lower 30-day mortality (hazard ratio, 0.79 [95% CI, 0.63-0.98]; P=0.03) without differences in various subgroups. Complications occurred more frequently in patients with left ventricular unloading: severe bleeding in 98 (38.4%) versus 45 (17.9%), access site-related ischemia in 55 (21.6%) versus 31 (12.3%), abdominal compartment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1%).

Conclusions: In this international, multicenter cohort study, left ventricular unloading was associated with lower mortality in patients with cardiogenic shock treated with VA-ECMO, despite higher complication rates. These findings support use of left ventricular unloading in patients with cardiogenic shock treated with VA-ECMO and call for further validation, ideally in a randomized, controlled trial.

Keywords: extracorporeal membrane oxygenation; shock, cardiogenic.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve of the unmatched study cohort. ECMELLA indicates Impella+extracorporeal membrane oxygenation; HR, hazard ratio; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.
Figure 2.
Figure 2.
Kaplan-Meier curve of the matched study cohort. ECMELLA indicates Impella+extracorporeal membrane oxygenation; HR, hazard ratio; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.
Figure 3.
Figure 3.
Association between ECMELLA use and 30-day all-cause mortality in prespecified subgroups. P interaction is 0.79 for age <52 years versus age 52 to 62 years, 0.95 for age <52 years versus age >62 years, and 0.82 for age 52 to 62 years versus age >62 years. P interaction is 0.23 for lactate <5 mmol/L versus 5 to 10.8 mmol/L, 0.20 for <5 mmol/L versus >10.8 mmol/L, and 0.90 for 5 to 10.8 mmol/L versus >10.8 mmol/L. P interaction is 0.55 for survival after venoarterial extracorporeal membrane oxygenation (SAVE) score >−6 versus −6 to −11, 0.99 for >−6 versus <−11, and 0.52 for −6 to −11 versus <−11. P interaction is 0.16 for Simplified Acute Physiology Score II (SAPS II) <52 versus −52 to 76, 0.21 for <52 versus >76, and 0.86 for 52 to 76 versus >76. AMI indicates acute myocardial infarction; CS, cardiogenic shock; ECMELLA, Impella+extracorporeal membrane oxygenation; eCPR, venoarterial extracorporeal membrane oxygenation–assisted cardiopulmonary resuscitation; HR, hazard ratio; NS, nonsignificant; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.
Figure 4.
Figure 4.
Association between ECMELLA use and severe bleeding in prespecified subgroups. P interaction is 0.30 for age <52 years versus age 52 to 62 years, 0.11 for age <52 years versus age >62 years, and 0.50 for age 52 to 62 years versus age >62 years. P interaction is 0.21 for lactate <5 mmol/L versus 5 to 10.8 mmol/L, 0.77 for <5 mmol/L versus >10.8 mmol/L, and 0.32 for 5 to 10.8 mmol/L versus >10.8 mmol/L. P interaction is 0.74 for survival after venoarterial extracorporeal membrane oxygenation (SAVE) score >−6 versus −6 to −11, 0.72 for >−6 versus <−11, and 0.97 for −6 to −11 versus <−11. P interaction is 0.70 for Simplified Acute Physiology Score II (SAPS II) <52 versus −52 to 76, 0.67 for <52 versus >76, and 0.41 for 52 to 76 versus >76. AMI indicates acute myocardial infarction; CS, cardiogenic shock; ECMELLA, Impella+extracorporeal membrane oxygenation; eCPR, venoarterial extracorporeal membrane oxygenation–assisted cardiopulmonary resuscitation; OR, odds ratio; NS, nonsignificant; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.
Figure 5.
Figure 5.
Association between ECMELLA use and intervention because of access site–related ischemia in prespecified subgroups. P interaction is 0.75 for age <52 years versus age 52 to 62 years, 0.95 for age <52 years versus age >62 years, and 0.82 for age 52 to 62 years versus age >62 years. P interaction is 0.62 for lactate <5 mmol/L versus 5 to 10.8 mmol/L, 0.52 for <5 mmol/L versus >10.8 mmol/L, and 0.23 for 5 to 10.8 mmol/L versus >10.8 mmol/L. P interaction is 0.58 for survival after venoarterial extracorporeal membrane oxygenation (SAVE) score >−6 versus −6 to −11, 0.51 for >−6 versus <−11, and 0.23 for −6 to −11 versus <−11. P interaction is 0.65 for Simplified Acute Physiology Score II (SAPS II) <52 versus −52 to 76, 0.64 for <52 versus >76, and 0.31 for 52 to 76 versus >76. AMI indicates acute myocardial infarction; CS, cardiogenic shock; ECMELLA, Impella+extracorporeal membrane oxygenation; eCPR, venoarterial extracorporeal membrane oxygenation–assisted cardiopulmonary resuscitation; NS, nonsignificant; OR, odds ratio; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.
Figure 6.
Figure 6.
Kaplan-Meier curves for all-cause mortality in patients receiving ECMELLA treated with early LV unloading and delayed LV unloading versus matched patients treated with only VA-ECMO. A, Only patients receiving ECMELLA in whom the Impella was implanted before or within 2 hours after the VA-ECMO implantation were considered for the matching; eg, matching patients with early LV unloading versus patients treated with VA-ECMO only. B, Only patients receiving ECMELLA in whom the Impella was implanted >2 hours after the VA-ECMO implantation were considered; eg, matching patients with delayed LV unloading versus patients treated with VA-ECMO only. ECMELLA indicates Impella+extracorporeal membrane oxygenation; HR, hazard ratio; LV, left ventricular; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.

Comment in

References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al. ; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128 - PubMed
    1. Becher PM, Schrage B, Sinning CR, Schmack B, Fluschnik N, Schwarzl M, Waldeyer C, Lindner D, Seiffert M, Neumann JT, et al. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation. 2018;138:2298–2300. doi: 10.1161/CIRCULATIONAHA.118.036691 - PubMed
    1. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40:2671–2683. doi: 10.1093/eurheartj/ehz363 - PubMed
    1. Brunner S, Guenther SPW, Lackermair K, Peterss S, Orban M, Boulesteix AL, Michel S, Hausleiter J, Massberg S, Hagl C. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2019;73:2355–2357. doi: 10.1016/j.jacc.2019.02.044 - PubMed
    1. Schrage B, Burkhoff D, Rübsamen N, Becher PM, Schwarzl M, Bernhardt A, Grahn H, Lubos E, Söffker G, Clemmensen P, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail. 2018;6:1035–1043. doi: 10.1016/j.jchf.2018.09.009 - PubMed